Abstract
Epithelial-mesenchymal transition (EMT) is an important biological process that is characteristic of malignant tumor cells with metastatic potential. We investigated the role of miR-551b in EMT and metastasis in gastric cancer (GC). We found that low miR-551b levels were associated with EMT, metastasis and a poor prognosis in GC patients. Further, two GC cell lines, MNK45 and SGC7901, exhibited lower miR-551b levels than the GES normal stomach cell line. Exposing MNK45 and SGC7901 cells to TGF-β1 resulted in cell morphology changes characteristic of EMT, which was confirmed by Western blot analysis demonstrating low E-Cadherin and high N-Cadherin and Vimentin levels. Treatment with miR-551b mimics inhibited these EMT changes as well as Transwell migration and invasiveness. We identified ERBB4 as a potential target of miR-551b based on patient data from the TCGA. ERBB4 was upregulated in GC specimens, and its high expression correlated with a poor prognosis of GC patients. Dual luciferase assays revealed that miR-551b directly inhibited ERBB4 by binding to its 3'UTR. Moreover, treatment with miR-551b mimics or the ERBB4 inhibitor AST-1306 inhibited EMT in the GC cell lines. Finally, nude mice xenografted with GC cancer cell line...Continue Reading
References
Nov 17, 1995·Science·J Mervis
Jul 19, 2003·Science·James C Carrington, Victor Ambros
Mar 29, 2008·Science·Oliver Hobert
Jan 21, 2009·Cell Research·Jian XuRik Derynck
Feb 4, 2010·Genome Biology·Ashley P E Roberts, Catherine L Jopling
Feb 26, 2011·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayDonald Maxwell Parkin
Jul 12, 2011·Physiological Reviews·Danish Sayed, Maha Abdellatif
Nov 16, 2011·Seminars in Oncology·Francesca LovatCarlo M Croce
Jun 2, 2012·The Lancet Oncology·Yi W KongMartin Bushell
Nov 21, 2012·Nature Reviews. Gastroenterology & Hepatology·Shumei Song, Jaffer A Ajani
Jan 15, 2013·Current Opinion in Cell Biology·Matthew T Blahna, Akiko Hata
Jan 22, 2013·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Aug 3, 2013·Nature Reviews. Immunology·Dirk Baumjohann, K Mark Ansel
Oct 2, 2013·Annual Review of Pathology·Gianpiero Di LevaCarlo M Croce
Nov 1, 2013·Nature Reviews. Drug Discovery·Hui LingGeorge A Calin
Feb 2, 2015·The Lancet Oncology·Sheraz R MarkarGeorge B Hanna
Mar 3, 2015·The Journal of Clinical Investigation·Matjaz RokavecHeiko Hermeking
Apr 22, 2015·Nature Medicine·Razvan CristescuAmit Aggarwal
Jul 15, 2015·Oncology Letters·Zhaofeng ChenYongning Zhou
Sep 22, 2015·Cancers·Arwa Flemban, David Qualtrough
Oct 3, 2015·CA: a Cancer Journal for Clinicians·Elizabeth M WardTed Gansler
Nov 6, 2015·Oncotarget·Yong QinShi-Ming Yang
Nov 13, 2015·Nature·Xiaofeng ZhengRaghu Kalluri
Jul 20, 2016·Journal of Clinical Medicine·Joema Felipe LimaJohn M S Bartlett
Nov 22, 2016·Nature Genetics·Ross A OkimotoTrever G Bivona
Citations
May 30, 2019·Cancers·Kwang Seock KimHyog Young Kwon
Oct 16, 2019·Journal of Cellular Physiology·Jie LiYu Jiang
Jun 15, 2019·Journal of Cellular and Molecular Medicine·Weiping ChangZhimin Geng
Mar 29, 2020·Cellular Oncology (Dordrecht)·Vincent F M SegersGilles W De Keulenaer
Sep 5, 2020·Cancer Reports·Sepideh KadkhodaJavad Tavakkoly-Bazzaz
Nov 20, 2018·Cancer Biomarkers : Section a of Disease Markers·Xiang WangHan Hui Yao
Apr 23, 2020·Molecular Medicine Reports·Xiaojing JiaYitao Jia
Jul 1, 2020·Bioscience, Biotechnology, and Biochemistry·Qing LvZhiyong Wang
Mar 19, 2020·Cells·Ainhoa LapitzJesus M Banales
May 26, 2018·Oncogene·Weilin LiJun Yu
Nov 17, 2020·Frontiers in Genetics·Nitish Kumar MishraChittibabu Guda
Dec 1, 2020·Cancer Gene Therapy·Tao JiZongbu Yu
Feb 25, 2021·DNA and Cell Biology·Yu GuanChaozhao Liang
Apr 20, 2021·Open Medicine·Qiang ChenQingping Cai